Company / R&D per Share
Celldex Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.68
FY2025
5-year range
$1.14 / $3.68
FY2021-FY2025
Trend
+49.5%
vs FY2024
Sector context
#14 of 109
Health Care
What the data says
Celldex Therapeutics, Inc.'s r&d per share of $3.68 is higher than 87% of companies in the Health Care sector (FY2025). R&D per Share has increased for 5 consecutive years, from $1.07 in FY2020 to $3.68 in FY2025.
Based on SEC 10-K filings.
3.68 in FY2025 with a 5-year CAGR of +27.9%. Top quartile in the Health Care sector.
Improved from $2.11 to $3.68 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +28.3%
- 5-Year CAGR
- +27.9%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 109This company $3.68 Sector average $2.08
▼
+77.3% above sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s r&d per share has grown for 5 consecutive years.
- In FY2025, r&d per share increased 49.5% year-over-year.
- Ranks #14 out of 109 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.68 | +49.5% |
| FY2024 | $2.46 | +16.7% |
| FY2023 | $2.11 | +21.2% |
| FY2022 | $1.74 | +52.8% |
| FY2021 | $1.14 | +6.2% |
| FY2020 | $1.07 | -57.3% |
| FY2019 | $2.51 | -77.4% |
| FY2018 | $11.12 | +1294.0% |
| FY2017 | $0.80 | -6.4% |
| FY2016 | $0.85 | -16.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026